TScan Therapeutics, Inc. (TCRX) Tops Q4 EPS by 9c
Tweet
Share
E-mailGet Alerts TCRX Hot Sheet
Join SI Premium – FREE
TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q4 EPS of ($0.18), $0.09 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $2.57 million versus the consensus estimate of $2.04 million.
For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jaguar Health (JAGX) Tops Q2 EPS by 3647c
- Barclays Starts Bitdeer Technologies Group (BTDR) at Overweight
- KeyBanc Upgrades EPR Properties (EPR) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
